Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seth P Lerner

Showing results (281-290 of 294) with videos related to

Pageof 30
Sort By:
Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder CancerSeth P Lerner, Dean F Bajorin, Colin P Dinney, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder CancerElaine Chang, Noah M Hahn, Seth P Lerner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2025
End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder CancerAndrea Necchi, Matthew D Galsky, Nazli Dizman, et al.
The Journal of Urology|May 5, 2024
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 TrialVikram M Narayan, Stephen A Boorjian, Mehrdad Alemozaffar, et al.
European Urology|February 11, 2020
Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434-5Aurélie Kamoun, Aurélien de Reyniès, Yves Allory, et al.
Cell|October 10, 2017
Comprehensive Molecular Characterization of Muscle-Invasive Bladder CancerA Gordon Robertson, Jaegil Kim, Hikmat Al-Ahmadie, et al.
The Lancet. Oncology|November 30, 2020
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trialStephen A Boorjian, Mehrdad Alemozaffar, Badrinath R Konety, et al.
Cell|August 11, 2018
Comprehensive Molecular Characterization of Muscle-Invasive Bladder CancerA Gordon Robertson, Jaegil Kim, Hikmat Al-Ahmadie, et al.
European Urology|December 22, 2021
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical TrialAnirban P Mitra, Vikram M Narayan, Sharada Mokkapati, et al.
Human Molecular Genetics|August 10, 2011
A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3Montserrat Garcia-Closas, Yuanqing Ye, Nathaniel Rothman, et al.
Pageof 30

Showing results (281-290 of 294) with videos related to

Sort By:
Pageof 30
Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder CancerSeth P Lerner, Dean F Bajorin, Colin P Dinney, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder CancerElaine Chang, Noah M Hahn, Seth P Lerner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2025
End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder CancerAndrea Necchi, Matthew D Galsky, Nazli Dizman, et al.
The Journal of Urology|May 5, 2024
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 TrialVikram M Narayan, Stephen A Boorjian, Mehrdad Alemozaffar, et al.
European Urology|February 11, 2020
Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434-5Aurélie Kamoun, Aurélien de Reyniès, Yves Allory, et al.
Cell|October 10, 2017
Comprehensive Molecular Characterization of Muscle-Invasive Bladder CancerA Gordon Robertson, Jaegil Kim, Hikmat Al-Ahmadie, et al.
The Lancet. Oncology|November 30, 2020
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trialStephen A Boorjian, Mehrdad Alemozaffar, Badrinath R Konety, et al.
Cell|August 11, 2018
Comprehensive Molecular Characterization of Muscle-Invasive Bladder CancerA Gordon Robertson, Jaegil Kim, Hikmat Al-Ahmadie, et al.
European Urology|December 22, 2021
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical TrialAnirban P Mitra, Vikram M Narayan, Sharada Mokkapati, et al.
Human Molecular Genetics|August 10, 2011
A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3Montserrat Garcia-Closas, Yuanqing Ye, Nathaniel Rothman, et al.
Pageof 30